Determining the Impact of Penicillin in Latent RHD: The GOAL Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 807 participants.

Also called NCT03346525

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 807 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03346525
Other papers using this trial's data
  • Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease The New England journal of medicine, 2022-01-20 DOI, PubMed 34767321

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Uganda (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03346525. Randomized; single masking; primary purpose treatment. Start 2018-06-26 (actual); primary completion 2020-11-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Determining the Impact of Penicillin in Latent RHD: The GOAL Trial
Acronym
GOAL
Condition
Rheumatic Heart Disease in Children
Condition
Latent Rheumatic Heart Disease
Condition
Rheumatic Heart Disease
Condition
Heart Diseases
Intervention (Drug)
intramuscular benzathine penicillin G (BPG) prophylaxis
Lead sponsor
Children's National Research Institute (class: other)
Collaborator
Thrasher Research Fund (class: other)
Collaborator
University of Cape Town (class: other)
Collaborator
Uganda Heart Institute (class: other)
Collaborator
Karp Family Foundation (class: not stated)
Collaborator
Gift of Life International (class: other)
Collaborator
Murdoch Childrens Research Institute (class: other)

Record details

Record id
cardio:ct-nct03346525
Content hash
313de4bd0d160cba2c4fbab872c99060356d68ed4f34abd4c8bd4a8b24642eee